Back
Compare AU
Compare DRUG vs. BBOZ
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the Betashares Aus Equities Strong Bear Complex ETF (BBOZ). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | BBOZ | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 74 | 12 |
Median incremental investment | $740.50 | $3,054.75 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,755.07 | $2,560.89 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | BBOZ | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | BBOZ.AX was created on 2015-04-17 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to help investors profit from, or protect against, a declining Australian share market. It seeks to generate magnified returns that are negatively correlated to the returns of the Australian share market (as measured by the S&P/ASX 200 Index) |
Top 3 holdings | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) | SPI 200 FUTURES MAR26 (0 %) AUD - AUSTRALIA DOLLAR (85.26 %) BETASHARES AUSTRALIAN CASH PLUS FUND (14.74 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | Other (68.91 %) Communication Services (31.09 %) |
Top 3 countries | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) | |
Management fee | 0.57 % | 1.38 % |
Key Summary
DRUG | BBOZ | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.57 % | 1.38 % |
Price | $8.71 | $21.43 |
Size | $176.672 million | $192.360 million |
10Y return | N/A | -19.35 % |
Annual distribution yield (5Y) | 1.92 % | 0.89 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 20/04/2015 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | BBOZ | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 74 | 12 |
Median incremental investment | $740.50 | $3,054.75 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,755.07 | $2,560.89 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | BBOZ | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | BBOZ |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |